Epidemiology and outcomes of marked elevations of alanine aminotransferase >1000 IU/L in an Australian cohort.
alanine aminotransferase
alanine transaminase
ischemic hepatitis
Journal
JGH open : an open access journal of gastroenterology and hepatology
ISSN: 2397-9070
Titre abrégé: JGH Open
Pays: Australia
ID NLM: 101730833
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
22
04
2019
revised:
03
06
2019
accepted:
05
06
2019
entrez:
14
4
2020
pubmed:
14
4
2020
medline:
14
4
2020
Statut:
epublish
Résumé
Marked elevations of alanine aminotransferase (ALT) are caused by a limited number of underlying pathologies, including hepatic ischemia, drugs/toxins, viral hepatitis, and-rarely-autoimmune hepatitis. The aim of this study was to determine the relative incidence of pathologies resulting in ALT greater than 1000 IU/L and factors predicting clinical outcomes in an Australian cohort. A retrospective cohort study of all adult patients with ALT levels greater than 1000 IU/L between January 2013 and December 2015 was conducted at a large teaching hospital network in Australia. Multivariable logistic regression analysis was used to determine predictors of etiology and mortality. There were 287 patients identified with ALT levels greater than 1000 IU/L. The most common causes were ischemia (44%), drugs/toxins (19%), biliary obstruction (16%), and viral hepatitis (7%). Independent predictors of a diagnosis of ischemic hepatitis included (adjusted odds ratio; 95% confidence interval): hypotension (29.2; 8.2-104.7), chronic obstructive pulmonary disease (COPD) (20.2; 2.8-145.3), coronary artery disease (12.9; 1.7-98.9), congestive cardiac failure (7.8; 1.2-49.2), diabetes mellitus (7.4; 1.6-33.9), metabolic acidosis (6.2; 2.0-19.4), gamma-glutamyltransferase < 135 IU/L (5.1; 1.5-17.6), and albumin <34 g/L (3.4; 1.1-11.0). Independent risk factors for all-cause 28-day mortality included: septic shock (14.7; 4.3-50.7), metabolic acidosis (7.3; 2.5-21.3), history of COPD (5.4; 1.6-17.8), cardiogenic shock (4.3; 1.6-11.7), prothrombin time ≥ 20 s (3.7; 1.5-9.2), and age ≥ 65 years (3.0; 1.3-7.2). Ischemic hepatitis was the most common cause of ALT levels greater than 1000 IU/L and was associated with high mortality.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Marked elevations of alanine aminotransferase (ALT) are caused by a limited number of underlying pathologies, including hepatic ischemia, drugs/toxins, viral hepatitis, and-rarely-autoimmune hepatitis. The aim of this study was to determine the relative incidence of pathologies resulting in ALT greater than 1000 IU/L and factors predicting clinical outcomes in an Australian cohort.
METHODS
METHODS
A retrospective cohort study of all adult patients with ALT levels greater than 1000 IU/L between January 2013 and December 2015 was conducted at a large teaching hospital network in Australia. Multivariable logistic regression analysis was used to determine predictors of etiology and mortality.
RESULTS
RESULTS
There were 287 patients identified with ALT levels greater than 1000 IU/L. The most common causes were ischemia (44%), drugs/toxins (19%), biliary obstruction (16%), and viral hepatitis (7%). Independent predictors of a diagnosis of ischemic hepatitis included (adjusted odds ratio; 95% confidence interval): hypotension (29.2; 8.2-104.7), chronic obstructive pulmonary disease (COPD) (20.2; 2.8-145.3), coronary artery disease (12.9; 1.7-98.9), congestive cardiac failure (7.8; 1.2-49.2), diabetes mellitus (7.4; 1.6-33.9), metabolic acidosis (6.2; 2.0-19.4), gamma-glutamyltransferase < 135 IU/L (5.1; 1.5-17.6), and albumin <34 g/L (3.4; 1.1-11.0). Independent risk factors for all-cause 28-day mortality included: septic shock (14.7; 4.3-50.7), metabolic acidosis (7.3; 2.5-21.3), history of COPD (5.4; 1.6-17.8), cardiogenic shock (4.3; 1.6-11.7), prothrombin time ≥ 20 s (3.7; 1.5-9.2), and age ≥ 65 years (3.0; 1.3-7.2).
CONCLUSIONS
CONCLUSIONS
Ischemic hepatitis was the most common cause of ALT levels greater than 1000 IU/L and was associated with high mortality.
Identifiants
pubmed: 32280751
doi: 10.1002/jgh3.12224
pii: JGH312224
pmc: PMC7144769
doi:
Types de publication
Journal Article
Langues
eng
Pagination
106-112Informations de copyright
© 2019 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Am J Med. 2015 Dec;128(12):1314-21
pubmed: 26299319
J Clin Epidemiol. 1993 Nov;46(11):1323-30
pubmed: 8229110
Medicine (Baltimore). 2016 Oct;95(42):e5176
pubmed: 27759652
Clin Chem. 2000 Dec;46(12):2027-49
pubmed: 11106349
J Clin Gastroenterol. 2017 Sep;51(8):728-733
pubmed: 27466169
Arch Intern Med. 1991 Feb;151(2):260-5
pubmed: 1992953
Prev Vet Med. 2000 May 30;45(1-2):23-41
pubmed: 10802332
J Investig Med High Impact Case Rep. 2016 May 18;4(2):2324709616651092
pubmed: 27408902
J Anesth. 2011 Feb;25(1):50-6
pubmed: 21153035
Gastroenterol Hepatol. 2005 Jan;28(1):15-9
pubmed: 15691463
Clin Med (Lond). 2015 Jun;15(3):244-7
pubmed: 26031973
Ann Intern Med. 2002 Jul 2;137(1):1-10
pubmed: 12093239
Best Pract Res Clin Gastroenterol. 2008;22(6):991-1008
pubmed: 19187863
Am J Gastroenterol. 1995 Aug;90(8):1244-5
pubmed: 7639223
J Gastroenterol Hepatol. 2013 Mar;28(3):522-9
pubmed: 22497339
J Clin Epidemiol. 1993 Nov;46(11):1331-6
pubmed: 8229111
Rev Esp Salud Publica. 2007 May-Jun;81(3):271-8
pubmed: 17694634
World J Hepatol. 2017 Aug 8;9(22):959-966
pubmed: 28839516
Scand J Gastroenterol. 2016;51(5):594-600
pubmed: 26653080
J Nucl Med. 1978 Feb;19(2):213-20
pubmed: 627904
Intensive Care Med. 2009 Aug;35(8):1397-405
pubmed: 19506833
J Crit Care. 2017 Oct;41:9-15
pubmed: 28460210
Gut. 1999 Jul;45(1):129-33
pubmed: 10369716
J Dig Dis. 2016 Mar;17(3):193-201
pubmed: 26879902
World J Gastroenterol. 2012 Nov 7;18(41):5972-8
pubmed: 23139615
CMAJ. 2005 Feb 1;172(3):367-79
pubmed: 15684121
Clin Gastroenterol Hepatol. 2019 May;17(6):1201-1203
pubmed: 30103039
Arch Intern Med. 2008 Mar 24;168(6):663-6
pubmed: 18362260